With Perjeta, The Cost Of HER2 Breast Cancer Therapy Goes Up
Executive Summary
Roche’s Perjeta will be priced at a premium to Herceptin and used in combination with it, more than doubling the cost of treating patients with HER2-positive metastatic breast cancer.
You may also be interested in...
Big Data’s Day Will Dawn Despite Big Questions, Experts Say
The complexity of molecular datasets and issues around their use, like cost, are enormous challenges in oncology applications, but not insurmountable, leaders at the Cancer Progress conference say.
Kadcyla Positioned For Wide Use In Metastatic Breast Cancer
Roche is set to launch T-DM1 at the price of $9,800 a month, similar to cost of the preferred first-line regimen, which includes a combination of its own Perjeta and Herceptin. Drug was tested mostly in second-line+ mBC, but labeling allows first-line treatment in a subset of patients at high risk.
Kadcyla Positioned For Wide Use In Metastatic Breast Cancer
Roche is set to launch T-DM1 at the price of $9,800 a month, similar to cost of the preferred first-line regimen, which includes a combination of its own Perjeta and Herceptin. Drug was tested mostly in second-line HER-2 positive mBC, but labeling allows first-line treatment in a subset of patients at high risk.